Dermatologic oncology
Hoth Therapeutics Inc. focuses on skin toxicities associated with epidermal growth factor receptor inhibitors, with clinical interest in treatment-related acneiform rash and related cutaneous adverse effects seen during cancer therapy.
- EGFR inhibitor–associated skin toxicity
- Acneiform rash
- Topical dermatologic therapy
The sponsor’s research activity centers on managing therapy-induced skin complications in patients receiving epidermal growth factor receptor inhibitor treatment.
Topical pharmacokinetics
Its clinical research includes evaluation of topical HT-001 with attention to pharmacokinetics after skin application, supporting interest in localized delivery for cutaneous conditions.
- Topical application
- Pharmacokinetic characterization
- Localized skin exposure
This area reflects a therapeutic focus on skin-directed treatment for patients affected by oncology-related dermatologic toxicities.
Symptom control in cancer care
The sponsor is involved in research addressing the supportive care burden of cancer therapy–related dermatologic adverse events, particularly symptoms that can affect treatment tolerance and continuity.
- Supportive oncology
- Cutaneous adverse events
- Treatment tolerability
Clinical interest extends to reducing the impact of rash and irritation associated with targeted anticancer therapies.
Multinational clinical development
Hoth Therapeutics Inc. conducts its clinical research across multiple countries and collaborating sites, supporting development in a multicenter oncology-dermatology setting.
- Collaborating research sites
- Active international trials
- Cross-site clinical evaluation
The sponsor’s funded research is concentrated in a single therapeutic domain, with activity directed toward practical management of EGFR inhibitor-related skin reactions.
